Receive our newsletter – data, insights and analysis delivered to you
  1. News
September 14, 2021

AzurRx BioPharma to acquire First Wave Bio for $229m

AzurRx’s management team comprising CEO James Sapirstein will remain in the role to lead the merged company.

AzurRx BioPharma has signed a definitive agreement to acquire First Wave Bio in a stock and cash deal valued at $229m, comprising specific development, regulatory and sales milestones.

A clinical-stage biotechnology company, First Wave Bio focuses on developing new, gut-targeted, small molecule treatments for auto-immune inflammatory bowel diseases (IBD) and various serious ailments.

In line with the transaction, AzurRx will be renamed to ‘First Wave BioPharma, Inc.’

The management team of AzurRx, including the chairman, president and CEO James Sapirstein, will continue to lead the renamed firm.

With the acquisition, AzurRx will gain complete rights to First Wave Bio’s proprietary formulations of niclosamide.

A small molecule drug, niclosamide possesses anti-viral as well as anti-inflammatory properties created to address various GI conditions.

Content from our partners
Extractables and leachables analysis in pharmaceutical quality control
How Hengst helped to keep Germany’s charity “star singers” shining
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success

In addition, AzurRx will fully own First Wave Bio’s strong intellectual property (IP) portfolio, which comprises the method of usage and delivery of these formulations as therapies for several auto-immune, inflammatory and viral ailments.

Sapirstein said: “The acquisition of First Wave Bio and the creation of First Wave BioPharma is a transformative event that significantly expands our GI development pipeline and positions our company for new growth opportunities in the inflammatory bowel disease therapeutic space.

“We believe that our proprietary formulations of niclosamide, with their novel anti-inflammatory mechanism of action, non-systemic absorption and safety benefits will enable us to address significant unmet clinical needs for IBD patients, especially in the mild-to-moderate disease categories.”

AzurRx in-licensed the exclusive international rights to develop oral and rectal formulations of niclosamide from First Wave Bio in January this year for Covid-19-associated GI infections and immune checkpoint inhibitor-associated colitis and diarrhoea (ICI-AC) in advanced-stage cancer patients.

On concluding the transaction, the internal development pipeline of AzurRx will comprise three new clinical IBD indications in ulcerative proctitis, ulcerative proctosigmoiditis, ulcerative colitis and Crohn’s disease.

The latest development comes after AzurRx activated seven study sites in India for the Phase II RESERVOIR clinical trial of its micronised niclosamide tablets, called FW-1022, to treat Covid-19-related GI infections.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy